本文選題：地西他濱 + CAG方案�。� 參考：《重慶醫(yī)科大學》2016年碩士論文

【摘要】：目的觀察地西他濱(DAC)聯(lián)合CAG方案對老年骨髓增生異常綜合癥的臨床療效和安全性。方法回顧性總結(jié)分析重慶醫(yī)科大學附屬第一醫(yī)院收治的20例老年確診為骨髓增生異常綜合征(MDS)接受地西他濱聯(lián)合CAG方案[地西他濱25mg/d,d1-5,qd,靜脈滴注;阿克拉霉素(ACR)10 mg/d,d3-6,qd,靜脈滴注;阿糖胞苷(Ara-C)10mgm-2d-1,d3-9,q12h,皮下注射;粒細胞集落刺激因子(G-CSF)200ugm-2d-1,d1-14,qd,皮下注射]治療的患者,觀察臨床療效。結(jié)果20例老年白血病患者經(jīng)過地西他濱聯(lián)合CAG化療后,緩解率(CR+mCR)為50%,總反應率(ORR,即CR+mCR+PR+HI)為90%。1年總生存(OS)率為82%,2年OS率為58%,平均總生存時間(14.15±11.21)月。結(jié)論地西他濱聯(lián)合CAG方案治療老年骨髓增生異常綜合癥,有較高的緩解率,非血液學不良反應小,耐受性良好。
[Abstract]:Objective to observe the clinical efficacy and safety of dicitabine combined with CAG regimen in elderly patients with myelodysplastic syndrome. Methods Twenty elderly patients with myelodysplastic syndromes diagnosed as myelodysplastic syndrome in the first affiliated Hospital of Chongqing Medical University were retrospectively analyzed. The clinical efficacy was observed in patients treated with cytosine arabinoside 10 mg / d ~ (-2) d ~ (-1) d _ (3) ~ (9) Q _ (12) h, and granulocyte colony stimulating factor G ~ (-CSF) -200ugn ~ (-2) d ~ (-1) d _ (1) D _ (1) ~ (14) Q _ d (subcutaneously). Results the remission rate (CR) was 50, the total response rate (CR mCR PR HI) was 82, the average survival time was 14. 15 鹵11. 21 months, and the average survival time was 14. 15 鹵11. 21 months after the chemotherapy with desitabine combined with CAG in 20 patients with senile leukemia. The total response rate was 82, and the 2 year OS rate was 58, and the average survival time was 14. 15 鹵11. 21 months. Conclusion Dietabine combined with CAG regimen in the treatment of elderly patients with myelodysplastic syndrome has a higher remission rate, less adverse non-hematological reactions and good tolerance.
【學位授予單位】：重慶醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2016
【分類號】：R551.3

【相似文獻】

相關(guān)期刊論文 前10條

1 ;地西他濱將在中國上市[J];臨床合理用藥雜志;2009年15期

2 李娟;嚴魯萍;許亞梅;;地西他濱配合中藥治療骨髓增生異常綜合征1例[J];貴陽中醫(yī)學院學報;2010年02期

3 高沖;陳寶安;劉苒;徐昕;丁家華;王駿;程堅;趙剛;余正平;宋慧慧;鮑文;;地西他濱治療骨髓增生異常綜合征一例報告[J];現(xiàn)代醫(yī)學;2010年02期

4 宋慧慧;陳寶安;劉苒;高沖;丁家華;孫耘玉;王駿;程堅;趙剛;余正平;鮑文;;地西他濱3d方案治療骨髓增生異常綜合征療效討論附兩例病例報道[J];東南大學學報(醫(yī)學版);2011年03期

5 譚振清;羅自勉;周新伏;;低劑量地西他濱治療骨髓增生異常綜合征的療效分析[J];現(xiàn)代腫瘤醫(yī)學;2012年08期

6 李倩;鄭智茵;;地西他濱治療中危骨髓增生異常綜合征2例并文獻復習[J];浙江中西醫(yī)結(jié)合雜志;2013年12期

7 朱小勤;邱仲川;陳s，

本文編號：1838269